Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02078609 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT02078609 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 70 participants.
The verdict
NCT02078609, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study will assess the safety and preliminary efficacy of escalating doses of LGH447 monotherapy in AML and MDS and LGH447 in combination with midostaurin in AML.
Interventions
- DRUG LGH447
- DRUG LGH447 + midostaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-03-20 |
| Est. Completion | 2019-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02078609
The ClinicalTrials.gov registry entry for NCT02078609 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LGH447 is the first listed.
NCT02078609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02078609 about?
NCT02078609 is a clinical study titled "A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)". This study will assess the safety and preliminary efficacy of escalating doses of LGH447 monotherapy in AML and MDS and LGH447 in combination with midostaurin in AML.
What is the current status of trial NCT02078609?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2014-03-20. Estimated completion is 2019-04-18.
What interventions are being tested in trial NCT02078609?
The interventions under investigation include: LGH447 (DRUG), LGH447 + midostaurin (DRUG).
Who is sponsoring clinical trial NCT02078609?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.